• Merck starts rolling BLA for Ebola vaccine

    • November 15, 2018
    • Posted By : admin
    • 0 Comment
    •   60 views

    Merck (NYSE:MRK) has initiated the rolling submission of its U.S. marketing application seeking approval for its vaccine for Ebola Zaire disease, V920 (rVSV∆G-ZEBOV-GP, live attenuated).

    V920 has Breakthrough Therapy status which provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.

    The company expects to complete the filing in 2019.

  60 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!